secwatch / observer
8-K filed May 7, 2026, 7:59 PM ET ticker DNA CIK 0001830214
earnings confidence high sentiment negative materiality 0.70

Ginkgo Bioworks Q1 revenue $19M (-49% YoY); narrows net loss; cash burn guidance reaffirmed

Ginkgo Bioworks Holdings, Inc.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Ginkgo Bioworks Holdings, Inc. reported the first quarter ended March 31, 2026 results: revenue $19 million, net income $(76) million. Guidance reaffirmed.

Period
the first quarter ended March 31, 2026
Revenue
$19 million
Net income
$(76) million
Guidance
reaffirmed
Result
reported results
Exact text from the filing
• First quarter 2026 Revenue of $19 million compared to $38 million in the comparable prior year period, a decrease of 49%. As previously reported, the first quarter of 2025 benefited from $7 million of non-cash revenue from previously announced release of deferred revenue relating to the mutual termination of a customer agreement. Excluding this non-cash deferred revenue release, first quarter 2026 Revenue of $19 million, down from $31 million in the comparable prior year period, a decrease of 37%. The decrease in revenue is primarily attributed to ongoing program rationalization as part of our restructuring activities. • First quarter 2026 GAAP net loss from continuing operations of $(76) million, compared to $(83) million in the comparable prior year period.
View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Ginkgo Bioworks Holdings, Inc. filing history →

Source: SEC EDGAR
accession 0001628280-26-032093
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.